sur GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Secures €1.7 Million in Fresh Fundraising
GenSight Biologics announced a successful fundraising of approximately €1.7 million, involving key shareholders Heights Capital, Invus, and UPMC Enterprises. This comes on the heels of several fundraisings in 2025, including a €4.5 million private placement and multiple smaller fundraisings. The recent investment employs a mixture of shares and warrants.
The funding helps to extend GenSight's cash reserves and supports the progression to the RECOVER Phase III trial. GenSight plans to leverage these resources to initiate treatments in France, Israel, and the United States, as part of their clinical expansion.
The fundraising activities are part of GenSight's broader strategy to ensure financial stability and operational continuity through 2026, despite unpredictable payment timings from the French hospital system. The shares and warrants issued are aligned with regulatory stipulations to facilitate their addition to Euronext Paris trading.
R. H.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENSIGHT BIOLOGICS S.A.